NCT00217399View on ClinicalTrials.gov

Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

July 31, 2009

Study Completion Date

January 31, 2013

Conditions
Recurrent Breast CancerStage IV Breast Cancer
Interventions
DRUG

sorafenib tosylate

Given orally

DRUG

anastrozole

Given orally

Trial Locations (1)

20057

Lombardi Comprehensive Cancer Center at Georgetown University, Washington D.C.

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00217399 - Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter